Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552905 | 0.84 | HRH3 (0.46) | HRH3CYP2D6HRH4CLK1DYRK1A | |
| SCHEMBL3543762 | 0.83 | HRH3 (0.48) | HRH3CYP2D6CNR2KMT2A | |
| SCHEMBL3538951 | 0.80 | CHRNA7 (0.50) | HRH3CYP2D6KMT2AMEN1 | |
| SCHEMBL3540527 | 0.78 | HRH3 (0.49) | HRH3CYP2D6 | |
| SCHEMBL3539153 | 0.78 | HRH3 (0.51) | HRH3CYP2D6 | |
| SCHEMBL1552607 | 0.78 | HRH3 (0.76) | HRH3CYP2D6 | |
| SCHEMBL1553114 | 0.77 | HRH3 (0.61) | HRH3CYP2D6 | |
| SCHEMBL3546171 | 0.76 | KMT2A (0.49) | HRH3CYP2D6CNR2KMT2AMEN1 | |
| SCHEMBL1553470 | 0.76 | ABCB11 (0.46) | HRH3CYP2D6CLK1DYRK1ADYRK1B | |
| SCHEMBL3540158 | 0.75 | HRH3 (0.40) | HRH3CYP2D6CNR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968967-B1 | 1,1-DIOXO-THIOMORPHOLINYL INDOLYL METHANONE DERIVATIVES FOR USE AS H3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2011-04-27 | — | — | EP | disclosed |
| US-7538101-B2 | 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20070123526-A1 | 1,1-Dioxo-thiomorpholinyl indolyl methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123526-A1 | 1,1-Dioxo-thiomorpholinyl indolyl methanone derivatives | MTNR1A, HTR1A, HRH4 | HRH3 4/4885CYP2D6 268/4885HRH4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.